by Truveta staff | Apr 1, 2025 | Research
GLP-1 drugs like Ozempic and Zepbound are transforming obesity treatment, yet 40-85% of patients are plagued by adverse GI events—particularly women. New research from Olio Labs, using Truveta Data, reveals that women experience nausea and vomiting at significantly...
by Truveta staff | Jul 30, 2024 | Data
By the time most women with ovarian cancer are diagnosed, 70-80% are already at an advanced stage of the disease. Despite declining mortality rates over the past decade, the 5-year survival rate for patients with ovarian cancer remains less than 30%. Sometimes...
